Cocaine Withdrawal Symptoms Identify “Type B” Cocaine-Dependent Patients

REFERENCES

• Kampman K, Volpicelli J R, McGinnis D E, et al. Reliability and validity of the cocaine selective severity assessment. Addict Behav. 1998; 23: 449–461
   PubMed Web of Science ®Google Scholar
• Kampman K, Alterman A I, Volpicelli J R, et al. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychol Addict Behav. 2001; 15: 52–59
   PubMed Web of Science ®Google Scholar
• Kampman K, Pettitnati H, Volpicelli J R, et al. Cocaine dependence severity predicts outcome in outpatients detoxification from cocaine and alcohol. Am J Addict. 2004; 13: 74–82
   PubMed Web of Science ®Google Scholar
• Mulvaney F, Alterman A I, Boardman C R, Kampman K. Cocaine abstinence symptomatology and treatment attrition. J Subst Abuse Treat. 1999; 16: 129–135
   PubMedGoogle Scholar
• Babor T F, Hofmann M, DelBoca F K, et al. Types of alcoholics, I: evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry. 1992; 49: 599–608
   PubMed Web of Science ®Google Scholar
• Cloninger C R. Neurogenetic adaptive mechanisms in alcoholism. Science 1987; 236: 410–416
   PubMed Web of Science ®Google Scholar
• Ball D M, Sharman D, Gibb R, Powell J F, Hillman A, Peters T, Murray R, Smith I. Association Between the C2 allele at the cytochrome P450IIE1 gene and alcohol induced liver disease, alcohol Korsakoff's syndrome or alcohol dependence syndrome. Drug Alcohol Depend Oct, 1995; 39(3)181–184
   Google Scholar
• Kranzler H, Lappalainen J, Nellissery M, Gelernter J. Association study of alcoholism subtypes with a functional promoter polymorphism in the serotonin transporter protein gene. Alcohol Clin Exp Res 2002; 26: 1330–1335
   Google Scholar
• Pettinati H M. The use of selective serotonone reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry 2001; 62: 26–31, (Suppl. 20)
   PubMed Web of Science ®Google Scholar
• Goveas J S, Csernansky J G, Coccaro E F. Platelet serotonin content correlates inversely with life history of aggression in personality-disordered subjects. Psychiatry Res. 2004; 126: 23–32
   PubMed Web of Science ®Google Scholar
• Buydens-Branchey L, Branchey M, Hudson J, Rothman M, Fergeson P, McKernin C. Serotonergic function in cocaine addicts: prolactin responses to sequential D,L-fenfluramine challenges. Biol Psychiatry. 1999; 45: 1300–1306
   PubMedGoogle Scholar
• Patkar A A, Berrettini W H, Mannelli P, et al. Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine-dependent individuals and healthy volunteers. Psychiatr Genet. 2004; 14: 25–32
   Google Scholar
• First M B, Spitzer R L, Gibbon M, Williams J BW. Structured Clinical Interview for DSM-IV Axis I Disorders—Subject Edition. Biometrics Research Department New York State Psychiatric Institute, New York 1996, (SCID-I/P, Version 2.0)
   Google Scholar
• Sobell L C, Sobell M B. Timeline follow-back: a technique for assessing self-reported ethanol consumption. Measuring Alcohol Consumption: Psychosocial and Biological Methods, J Allen, R Z Litten. Humana Press, Totowa, New Jersey 1992; 41–72
   Google Scholar
• Kampman K, Volpicelli J R, Mulvaney F, et al. Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence. Addict Behav. 2002; 27: 251–260
   PubMed Web of Science ®Google Scholar
• Pettinati H M, Volpicelli J R, Kranzler H R, Luck G, Rukstalis M R, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000; 24: 1041–1049
   PubMed Web of Science ®Google Scholar
• Kranzler H R, Burleson J A, Brown J, Babor T F. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res 1996; 20: 1534–1541
   PubMed Web of Science ®Google Scholar
• Johnson B A, Roache J D, Javors M A, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000; 284: 963–971
   PubMed Web of Science ®Google Scholar
• Batki S L, Manfredi L B, Jacob P, III, Jones R T. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. J Clin Psychopharmacol. 1994; 14: 360–361
   Google Scholar
• Grabowski J, Rhoades H, Elk R, et al. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J Clin Psychopharmacol 1995; 15: 163–174
   PubMed Web of Science ®Google Scholar
• Winhusen T M, Somoza E C, Harrer J M, et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005; 100: 68–77, (Suppl. 1)
   PubMedGoogle Scholar